Nationwide Fund Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Nationwide Fund Advisors’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-14,841	Closed	-$79K	–	3409
2016 Q1	$79K	Buy	14,841 +1,673	+13%	+$13.4K	﹤0.01%	2889
2015 Q4	$162K	Buy	13,168 +2,357	+22%	+$31.5K	﹤0.01%	2646
2015 Q3	$158K	Hold	10,811	–	–	﹤0.01%	2689
2015 Q2	$211K	Sell	10,811 -266	-2%	-$5.13K	﹤0.01%	2687
2015 Q1	$200K	Sell	11,077 -136	-1%	-$3.06K	﹤0.01%	2694
2014 Q4	$265K	Buy	11,213 +855	+8%	+$19.8K	﹤0.01%	2504
2014 Q3	$251K	Buy	10,358 +80	+0.8%	+$2.08K	﹤0.01%	2587
2014 Q2	$289K	Buy	10,278 +243	+2%	+$7.3K	﹤0.01%	2551
2014 Q1	$341K	Buy	10,035 +59	+0.6%	+$2.02K	﹤0.01%	2247
2013 Q4	$192K	Buy	9,976 +1,049	+12%	+$19.1K	﹤0.01%	2709
2013 Q3	$146K	Buy	8,927 +5,333	+148%	+$61.8K	﹤0.01%	2811
2013 Q2	$38K	Buy	+3,594	New	+$42.1K	﹤0.01%	3008

Other funds holding CTIC

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Nationwide Fund Advisors's CTIC Position: Q2 2016 in Review

Nationwide Fund Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2016, closing a stake of 14,841 shares — an estimated $79K sold.

Nationwide Fund Advisors first reported a position in CTIC in Q2 2013 and held it in 12 quarters. The position peaked at $341K in Q1 2014. 67 funds tracked by Wall St. Rank hold CTIC as of Q2 2016.

Nationwide Fund Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2016 after selling out during the quarter.
Nationwide Fund Advisors sold 14,841 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2016, an estimated $79K.
Nationwide Fund Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 12 quarters.
Nationwide Fund Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $341K in Q1 2014.
67 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2016.

Based on Nationwide Fund Advisors's 13F filing for Q2 2016, filed 9 Aug 2016.